Last reviewed · How we verify
NCT05879172
Electric Tubular Anastomosis in Rectal Cancer
NA trial testing electric tubular anastomotic device in Anastomosis in 400 participants. Completed in 31 March 2023.
31 July 2022
Quick facts
| Lead sponsor | LI XIN-XIANG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 1 July 2021 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- electric tubular anastomotic device
- traditional anastomotic device
Conditions studied
- Anastomosis — all drugs for Anastomosis →
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
LI XIN-XIANG — full company profile →
Who can join
Adults 18 to 80, any sex, with Anastomosis or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Compared with traditional manual suturing, mechanical anastomosis can reduce the error caused by human factors. The electric anastomotic device can improve the automation and accuracy of anastomosis, reduce the requirements for doctors' operation, and establish a more standardized usage specification, thereby reducing the surgical complication rate and improving the quality of anastomosis. The clinical study of electric tubular anastomotic device adopts a multicenter, randomized, parallel controlled non-inferior study design, and randomly groups according to the 1:1 ratio to evaluate the clinical effectiveness and safety of electric tubular anastomotic device compared with conventional manual device.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Systemic assessment of manual circular stapler versus powered circular stapler for anastomosis in rectal cancer: a large-scale Chinese multicenter prospective cohort study.
Chen Y, Zhang R, Fan J, Luo D, et al · · 2025 · cited 1× · PMID 39166942 · DOI 10.1097/js9.0000000000002010
Verify or expand the search:
- PubMed search for NCT05879172
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anastomosis
Currently open trials in the same condition.
- NCT06222645 — PPG vs. ICG in Gastrointestinal Resections · NA · recruiting
Other LI XIN-XIANG trials
Trials by the same sponsor.
- NCT06423924 — Second Primary Cancer and Early-onset Colorectal Cancer · not yet recruiting
- NCT05359406 — A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis · Phase 2 · unknown
- NCT04759820 — Carbon Nanoparticles vs Indocyanine Green · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05879172 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LI XIN-XIANG
- Last refreshed: 30 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05879172.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing